H. yanyuanensis Bdellin Family Expansion (2025)
8.7–25× lineage-specific expansion of the bdellin gene family in the terrestrial blood-feeding leech Haemadipsa yanyuanensis — Lin 2025 chromosome-level genome.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- 8.7–25× lineage-specific expansion of the bdellin gene family in the terrestrial blood-feeding leech Haemadipsa yanyuanensis — Lin 2025 chromosome-level genome.
- Evidence level
- Mechanistic discussion
- Drug vs leech
- Purified natural compound
Clinical translation limit
Bdellin family expansion is documented at genome / phylogenetic level only; functional in vitro / in vivo characterization is pending. No FDA-approved derivative; H. yanyuanensis is not on the FDA K040187 cleared device species list.
Molecular Profile
- Category
- Proteinase Inhibitor
- Evidence tier
- Preclinical
- Source species
- Haemadipsa yanyuanensis
- Discovered
- 2025 · Lin Y et al.
Biological Targets
- → trypsin / plasmin (predicted by bdellin Kazal-domain homology)
Key Citations
- Lin Y et al. (2025), BMC Genomics · PMID 41469844
External Resources
Related Proteinase Inhibitor Compounds
Hirustasin
Serine proteinase inhibitor targeting tissue kallikrein — anti-inflammatory pathway.
Eglin C
Potent inhibitor of human leukocyte elastase and cathepsin G — anti-inflammatory protein widely used as research tool.
Bdellin B3
Kazal-type proteinase inhibitor targeting trypsin and plasmin — modulates inflammatory cascade.
LDTI (Leech-Derived Tryptase Inhibitor)
Selective inhibitor of human mast cell tryptase — anti-inflammatory pathway.